Breast Cancer Clinical Trial

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients

Summary

This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved cognitive and affective outcomes when compared to the standard of care delivery model.

View Full Description

Full Description

Cancer genetic testing has become a standard evidence-based practice, with established risk reduction and cancer screening guidelines for genetic carriers. With FDA approval for PARP inhibitors in patients with advanced breast, ovarian, pancreatic and prostate cancer, there is an additional therapeutic rationale for testing all breast, ovarian, pancreatic and prostate cancer patients for germline genetic mutations. Yet, access to genetic specialists is limited in many area, and the traditional model of pre- and post-test counseling with a genetic professional will not support the rising indications for cancer genetic testing. Thus, there is an urgent need to consider alternative delivery models to increase access and uptake of testing, while maintaining adequate patient outcomes.

This study aims to assess if traditional pre-test (visit 1) and post-test (visit 2: disclosure) counseling delivered by a genetic counselor can be replaced with a self-directed web-based eHealth intervention to provide critical data to inform optimal ways to deliver cancer genetic testing in patients with breast, ovarian, pancreatic and prostate cancer, while maintaining quality of care and favorable cognitive, affective and behavioral outcomes.

Specific Aim 1: To determine if web-based eHealth delivery of pre-test and/or post-test counseling can provide equal or improved cognitive and affective short-term and 6-month outcomes as compared to the two-visit standard of care delivery model with a genetic counselor. The investigator's primary outcomes will be changes in knowledge and anxiety. Secondary outcomes will include uptake of testing, depression, cancer specific distress, uncertainty and health behaviors and provider time.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

18 years of age or older
Speak and understand English
Male or Female

A personal history of one or more of the following:

metastatic breast cancer
advanced ovarian cancer (Stage III-IV)
metastatic pancreatic cancer
metastatic prostate cancer
Naive to previous cancer germline genetic testing

Exclusion Criteria:

Communication difficulties such as:

Uncorrected or uncompensated hearing and/or vision impairment
Uncorrected or uncompensated speech defects
Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks

Study is for people with:

Breast Cancer

Estimated Enrollment:

560

Study ID:

NCT04353973

Recruitment Status:

Recruiting

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Abramson Cancer Center at University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States More Info
Angela Bradbury, MD
Contact
[email protected]
Angela Bradbury, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

560

Study ID:

NCT04353973

Recruitment Status:

Recruiting

Sponsor:


Abramson Cancer Center of the University of Pennsylvania

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider